Stryker Completes First European Surgeries with Everlast, Adaptis Total Ankles

Stryker announced successful completion of the first surgeries in Europe using its Infinity total ankle system with Adaptis and Everlast technology.
 
The first procedures were performed by David N. Townshend FRCS (Orth), Consultant Trauma & Orthopaedic Surgeon at North Tyneside General Hospital, UK. These surgeries are also the beginning of the UK Infinity with Adaptis and Everlast study.
 
“We are delighted to have implanted the first patient using Stryker’s Infinity Total Ankle System with Adaptis and Everlast technology as part of the UK post-market clinical study,” said Townshend. “This new technology marks the next step of the Infinity Total Ankle System which has already shown promising outcomes and survivorship for our patients with end stage ankle arthritis. We look forward to sharing the results of this clinical study.”
 
The Infinity total ankle is composed of a titanium alloy tibial tray, cobalt chromium talar dome, and polyethylene insert. It also has a low-profile tibial implant design.
 
Adaptis 3D-printed total ankle implants use porous metal components to act as a scaffold to facilitate bony ingrowth, according to Stryker. Everlast highly cross-linked polyethylene inserts are blended with vitamin E to boost wear resistance, the company also said.
 
The two talar options are interchangeable to add versatility to the system, addressing diverse patient needs. The system is also optimized with Stryker’s Prophecy Surgical Planning, which features patient-specific instruments.
 
“Infinity with Adaptis builds on the legacy of the original Infinity Total Ankle, with a decade of clinical use. Recent publication data showed a 98.8% survivorship at two years of the original Infinity implant, demonstrating its safety and efficacy as a low-profile prosthesis for surgeons treating end-stage ankle arthritis,” said Markus Ochs, VP and GM of Stryker’s European Trauma & Extremities business. “These initial procedures highlight Stryker’s dedication to innovation and commitment through research, enhancing our collaboration with surgeons.”